China guideline for the screening and early detection of prostate cancer (2022, Beijing).
10.3760/cma.j.cn112152-20211226-00975
- Author:
Jie HE
1
;
Wan Qing CHEN
1
;
Ni LI
1
;
Wei CAO
1
;
Ding Wei YE
2
;
Jian Hui MA
1
;
Nian Zeng XING
1
;
Ji PENG
3
;
Jin Hui TIAN
4
Author Information
1. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
2. Fudan University Shanghai Cancer Center, Shanghai 200032, China.
3. Shenzhen Center for Chronic Disease Control and Prevention, Shenzhen 518020, China.
4. Evidence-Based Medicine Center of Lanzhou University, Lanzhou 730000, China.
- Collective Name:China Prostate Cancer Screening and Early Diagnosis and Early Treatment Guidelines Development Expert Group;Working Group on Formulation of Guidelines for Prostate Cancer Screening, Early Diagnosis and Early Treatment in China
- Publication Type:Journal Article
- Keywords:
China;
Early diagnosis and treatment;
Guideline;
Prostate neoplasms;
Screening
- MeSH:
Aged;
Beijing;
China/epidemiology*;
Early Detection of Cancer;
Humans;
Male;
Mass Screening;
Prostatic Neoplasms/epidemiology*
- From:
Chinese Journal of Oncology
2022;44(1):29-53
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer (PC) is one of the malignant tumors of the genitourinary system that occurs more often in elderly men. Screening, early diagnosis, and treatment of the PC high risk population are essential to improve the cure rate of PC. The development of the guideline for PC screening and early detection in line with epidemic characteristics of PC in China will greatly promote the homogeneity and quality of PC screening. This guideline was commissioned by the Bureau of Disease Control and Prevention of the National Health Commission. The National Cancer Center of China initiated and convened a working group comprising multidisciplinary experts. This guideline strictly followed the World Health Organization Handbook for Guideline Development and combined the most up-to-date evidence of PC screening, China's national conditions, and practical experience in cancer screening. A total of fifteen detailed evidence-based recommendations were provided with respect to the screening population, technology, procedure management, and quality control in the process of PC screening. This guideline aimed to standardize the practice of PC screening and improve the effectiveness and efficiency of PC prevention and control in China.
